Substance / Medication

Irinotecan hydrochloride

SNOMED 386912006 UMLS C0594375

Overview

Clinical overview including description, indications, and evidence base is pending physician authorship or FDA SPL integration. Graph-derived relationship data is available below.

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Non-small cell lung cancer

Administration & Protocol

Dosing, route, and treatment protocol

Administration details including route, dosing schedules, preparation instructions, and contraindications are pending physician authorship.

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Clinical Trials

58 trials linked to this intervention

Total Trials

Recruiting

With Results

Recent Trials

Bone Marrow Transplantation in Treating Patients With Hematologic Cancer

NCT00003398Phase 4Completed45 enrolled

Specimen Collections From Participants With HIV Infection, KSHV Infection, Viral-Related Pre-malignant Lesions and Cancer

NCT00006518Recruiting1029 enrolled

Clinical, Laboratory and Epidemiologic Characterization of Individuals and Families at High Risk of Hematologic Cancer

NCT00039676Active Not Recruiting1836 enrolled

Subcutaneous Amifostine Safety Study

NCT00158041Phase 4Completed452 enrolled

German Multicenter Trial for the Treatment of Newly Diagnosed T-lymphoblastic Lymphoma in Adults

NCT00199017Phase 4Completed75 enrolled

View all 58 trials on ClinicalTrials.gov

Research Evidence

Published studies and systematic reviews

Sort:

Irinotecan hydrochloride liposome HR070803 in combination with 5-fluorouracil and leucovorin in locally advanced or metastatic pancreatic ductal adenocarcinoma following prior gemcitabine-based therapy (PAN-HEROIC-1): a phase 3 trial.

Cui Jiujie, Qin Shukui, Zhou Yuhong et al. · Signal Transduct Target Ther · 2024

PMID: 39300077RCTFull text (PMC)

Phase II study of neoadjuvant chemotherapy with irinotecan hydrochloride and nedaplatin followed by radical hysterectomy for bulky stage Ib2 to IIb, cervical squamous cell carcinoma: Japanese Gynecologic Oncology Group study (JGOG 1065).

Yamaguchi Satoshi, Nishimura Ryuichiro, Yaegashi Nobuo et al. · Oncol Rep · 2012

PMID: 22614251Trial

N0332 phase 2 trial of weekly irinotecan hydrochloride and docetaxel in refractory metastatic breast cancer: a North Central Cancer Treatment Group (NCCTG) Trial.

Tan W W, Hillman D W, Salim M et al. · Ann Oncol · 2010

PMID: 19625343TrialFull text (PMC)

Irinotecan hydrochloride (CPT-11) in dialysis patients with gastrointestinal cancer.

Ashizawa Tatsuto, Iwahori Tohru, Yokoyama Takayoshi et al. · Acta Med Okayama · 2010

PMID: 20200580Trial

Pharmacokinetic and pharmacodynamic investigation of irinotecan hydrochloride in pediatric patients with recurrent or progressive solid tumors.

Kimura T, Kashiwase S, Makimoto A et al. · Int J Clin Pharmacol Ther · 2010

PMID: 20420789Trial

Phase I study of combination chemotherapy with irinotecan hydrochloride and nedaplatin for cervical squamous cell carcinoma: Japanese gynecologic oncology group study.

Yamamoto Kaichiro, Kokawa Katsuji, Umesaki Naohiko et al. · Oncol Rep · 2009

PMID: 19288001Trial

[A pilot study of irinotecan hydrochloride(CPT-11)and cisplatin(CDDP)combination chemotherapy for previously treated non-small cell lung cancer].

Tanaka Aya, Aragane Naoko, Komiya Kazutoshi et al. · Gan To Kagaku Ryoho · 2008

PMID: 18195527Trial

Salvage chemotherapy with a combination of irinotecan hydrochloride and mitomycin C in elderly Japanese patients with gynecological malignancies: a pilot study.

Tanaka Hirohiko, Kihira Tomohisa, Nomura Yoshiyuki et al. · J Infect Chemother · 2006

PMID: 16944263Trial

Irinotecan hydrochloride (CPT-11) and mitomycin C as the first line chemotherapy for ovarian clear cell adenocarcinoma.

Nishino Koji, Aoki Yoichi, Amikura Takayuki et al. · Gynecol Oncol · 2005

PMID: 15894369Trial

Phase I study of the combination of irinotecan hydrochloride, carboplatin, and dexamethasone for the treatment of relapsed or refractory malignant lymphoma.

Suzumiya Junji, Suzushima Hitoshi, Maeda Kouichi et al. · Int J Hematol · 2004

PMID: 15168596Trial

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type: Substance / Medication
Fully Specified Name: Irinotecan hydrochloride (substance)
SNOMED CT: 386912006
UMLS CUI: C0594375

Clinical Data

This intervention maps to 8 entities in the Ltrl knowledge graph.

Conditions

Biomarkers

Specialists

Symptoms

Clinical Trials

Data is sourced from SNOMED CT, UMLS, and the Ltrl clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.